Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
Shuai Xia(Shanghai Medical College of Fudan University), Lu Lu(Shanghai Medical College of Fudan University), Chen Hua(Shanghai Jiao Tong University), Ge Sun(National Institute for Radiological Protection), Fanke Jiao(Fudan University), Qiaoshuai Lan(Chinese University of Hong Kong), Shibo Jiang(Shanghai Medical College of Fudan University), Yang Wu(Wuhan University), Jan Münch(Universität Ulm), Frank Kirchhoff(Universität Ulm), Yun Zhu(Chinese Academy of Sciences), Zhenghong Yuan(Shanghai Medical College of Fudan University), Huan Liu(University of Hong Kong), Qian Wang(Shanghai Medical College of Fudan University), Fei Sun(University of California, Los Angeles), Chao Wang, Youhua Xie(Shanghai Medical College of Fudan University), Xia Cai(Fudan University), Jie Zhou(Fudan University), Jie Gao(Institute of Microbiology), Lijue Wang(Fudan University), Yutang Li(Shanghai Medical College of Fudan University), Wei Xu(Beijing Geriatric Hospital)
Cited by 68
Related Papers
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Absence of Intact nef Sequences in a Long-Term Survivor with Nonprogressive HIV-1 Infection
|New England Journal of Medicine|1995|1k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647